menu search

MOLN / Molecular Partners shares tumble 37% after Amgen returns rights to tumor treatment candidate

Molecular Partners shares tumble 37% after Amgen returns rights to tumor treatment candidate
Shares of Molecular Partners Inc. MOLN, -36.67% slid 37.3% in premarket trading on Wednesday, the day after the company said Amgen Inc. AMGN, -0.91% returned the global rights to an investigational oncology therapy currently in a Phase 1 clinical trial targeting solid tumors. Amgen's stock was up 0.3% in the premarket on Wednesday. Read More
Posted: Apr 27 2022, 08:02
Author Name: Market Watch
Views: 103188

MOLN News  

Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and Exposition

By GlobeNewsWire
November 2, 2023

Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and Exposition

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG ( more_horizontal

Molecular Partners to Present on its Radio DARPin Therapy (RDT) Platform at SNMMI 2023

By GlobeNewsWire
June 27, 2023

Molecular Partners to Present on its Radio DARPin Therapy (RDT) Platform at SNMMI 2023

RDT platform offers unique approach for tailored delivery of radioactive payloads to solid tumors RDT platform is focused on improving both tumor-targ more_horizontal

Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit

By GlobeNewsWire
June 19, 2023

Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 19, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage more_horizontal

Molecular Partners to Present Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 ASCO Annual Meeting

By GlobeNewsWire
May 25, 2023

Molecular Partners to Participate in RBC Capital 2023 Global Healthcare Conference

By GlobeNewsWire
May 16, 2023

Molecular Partners to Participate in RBC Capital 2023 Global Healthcare Conference

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 16, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage b more_horizontal

Molecular Partners: Sellers Have Disappeared, Enterprise Value Below Zero

By Seeking Alpha
April 20, 2023

Molecular Partners: Sellers Have Disappeared, Enterprise Value Below Zero

Molecular Partners: Sellers Have Disappeared, Enterprise Value Below Zero. more_horizontal

Molecular Partners to Present Additional Preclinical Data Supporting the Company's Radio DARPin Therapy Platform at AACR

By GlobeNewsWire
April 14, 2023

Molecular Partners to Present Additional Preclinical Data Supporting the Company's Radio DARPin Therapy Platform at AACR

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 14, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stag more_horizontal

Molecular Partners AG (MOLN) Q4 2022 Earnings Call Transcript

By Seeking Alpha
March 10, 2023

Molecular Partners AG (MOLN) Q4 2022 Earnings Call Transcript

Molecular Partners AG (NASDAQ:MOLN ) Q4 2022 Earnings Conference Call March 10, 2023 8:00 AM ET Company Participants Seth Lewis - Senior Vice Presiden more_horizontal


Search within

Pages Search Results: